

ASX Announcement 8 April 2019

#### **Appendix 3B**

In accordance with Appendix 6A of the ASX Listing Rules, Gulf Manganese Corporation Limited (ASX: GMC) ("Gulf" or "the Company") provides the following Appendix 3B that is required to be lodged in respect of the remaining GMCO options exercisable at \$0.005 each and due to expire on 21 April 2019.

This represents the maximum number of shares that may be issued on or about 14 May 2019, should all of the GMCO options be exercised. These options have not yet been converted into ordinary shares and will only be issued upon payment of the exercise price. Any further exercise of options will be announced to the ASX upon the issue of the shares.

As at the time of this announcement, the Company has 3,857,028,377 fully paid ordinary shares on issue and 1,739,099,886 GMCO options which may still be exercised.

The Appendix 3B also includes an application for quotation of shares offered under the Company's prospectus dated 1 April 2019.

-ENDS-

#### For further information please contact:

Hamish Bohannan Managing Director

Gulf Manganese Corporation Limited

T: 08 9367 9228

E: info@gulfmanganese.com

Released through Sam Burns, Six Degrees Investor Relations, M: +61 400 164 067



T4, 152 Great Eastern Highway Ascot WA 6104

Phone +61 8 9367 9228 Fax +61 8 9367 9229

Email info@gulfmanganese.com

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.<sup>1</sup>

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Gulf Manganese Corporation Limited
------------------------------------

ABN

73 059 954 317

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- Fully Paid Ordinary Shares
- Number of +securities issued or to be issued (if known) or maximum number which may be issued
- Up to 1,739,099,886 Shares on the exercise of listed options, exercisable at \$0.005 which expire on 21 April 2019 (Listed Options).
- Up to 5,000 Shares under the Offer set out in the Company's prospectus dated 1 April 2019 (Prospectus).
- 3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Fully Paid Ordinary Shares

<sup>+</sup> See chapter 19 for defined terms.

# New issue announcement

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment	Yes
	<ul> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	
5	Issue price or consideration	<ol> <li>\$0.005 per Share (exercise price of Listed Options)</li> <li>\$0.015 per Share (as set out in the Prospectus)</li> </ol>
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ol> <li>To be issued upon exercise of 1,739,099,886 Listed Options.</li> <li>For the purposes of section 708A(11) of the Corporations Act 2001 (Cth). For further details please refer to the Prospectus.</li> </ol>
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the <sup>+</sup> securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	19 November 2018
6c	Number of *securities issued without security holder approval under rule 7.1	Nil – the 5,000 Shares offered under the Prospectus have not been issued nor have been agreed to be issued by the Company.
6d	Number of <sup>+</sup> securities issued with security holder approval under rule 7.1A	Nil

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of <sup>+</sup> securities issued under an exception in rule 7.2		39,099,886 Shares will be issued upon exercise of ted Options under Listing Rule 7.2 exception 4
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Ref	fer to Annexure 1.
7	<sup>+</sup> Issue dates	1.	On or around 14 May 2019
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	2.	Closing Date under the Prospectus is 15 April 2019 (or such other closing date as may be set out in any supplementary or replacement prospectus amending the Prospectus)
	Cross reference: item 33 of Appendix 3B.		

Number and \*class of all
\*securities quoted on ASX
(including the \*securities in section
2 if applicable)

Number +Class

Issued:
3,857,028,377 Fully Paid Ordinary Shares

To be issued:
1,739,099,886 Fully Paid Ordinary Shares

5,000 Fully Paid Ordinary Shares

<sup>+</sup> See chapter 19 for defined terms.

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
50,000,000	Unlisted Options expiring 5 September 2021 at \$0.02
24,000,000	Unlisted Options expiring 5 September 2021 at \$0.02 (ECSOP)
18,000,000	Performance Rights expiring 28 November 2019 (Directors)
16,000,000	Performance Rights expiring 28 November 2019 (Employees)
31,500,001	Performance Rights vesting 31 December 2019 (Directors)
33,606,668	Performance Rights vesting 31 December 2019 (Employees)
25,000,000	Unlisted Options expiring 31 December 2020 at \$0.02
25,000,000	Unlisted Options expiring 31 December 2020 at \$0.03
6,725,083	Performance Rights vesting 5 March 2021 (Directors)
6,725,083	Performance Rights vesting 5 March 2022 (Directors)
7,908,050	Performance Rights vesting 5 March 2021 (Employees)
7,908,050	Performance Rights vesting 5 March 2022 (Employees)

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

# Part 2 - Pro rata issue

11 Is security holder approval required?

N/A

12 Is the issue renounceable or non-renounceable?

N/A

13 Ratio in which the <sup>+</sup>securities will be offered

N/A

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B

# New issue announcement

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A		
28	Date rights trading will begin (if applicable)	N/A		
29	Date rights trading will end (if applicable)	N/A		
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A		
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A		
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A		
33	<sup>+</sup> Issue date	N/A		
Part 3 - Quotation of securities  You need only complete this section if you are applying for quotation of securities  Type of *securities				
(a)	(tick one)  +Securities described in Part 1			
(b)	All other <sup>+</sup> securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities			
Entities that have ticked box 34(a)				
Additional securities forming a new class of securities				
Tick to i docume	indicate you are providing the information nts	or		
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders			

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000  100,001 and over			
37	A copy of any trust deed for the additional *securities			
Entities that have ticked box 34(b)				
38	Number of *securities for which *quotation is sought	N/A		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	N/A		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	N/A		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another +security, clearly identify that other +security)	N/A		
		Number	+Class	
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in clause 38)	N/A	N/A	

### **Quotation agreement**

<sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.

<sup>+</sup> See chapter 19 for defined terms.

- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

**Hamish Bohannan** 

(Managing Director and CEO)

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B - Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital  Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<ul> <li>Add the following:</li> <li>Number of fully paid         <sup>+</sup>ordinary securities issued in         that 12 month period under         an exception in rule 7.2</li> </ul>	4,000,000 shares issued 18/6/18 after exercise of listed options (LR 7.2 Ex 4) 4,000,000 shares issued 28/6/18 after exercise of listed options (LR 7.2 Ex 4) 82,106,667 shares issued 12/7/18 after exercise of	
<ul> <li>Number of fully paid         <sup>+</sup>ordinary securities issued in         that 12 month period with         shareholder approval</li> </ul>	listed options (LR 7.2 Ex 4) 18,317,712 shares issued 6/8/18 after exercise of listed options (LR 7.2 Ex 4) 77,350,000 shares issued in August 2018 after exercise of listed options (LR 7.2 Ex 4)	
<ul> <li>Number of partly paid     <sup>+</sup>ordinary securities that     became fully paid in that 12     month period</li> </ul>	23,950,000 shares issued in September 2018 after exercise of listed options (LR 7.2 Ex 4) 10,000,000 shares issued in October 2018 after exercise of listed options (LR 7.2 Ex 4)	
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items	6,534,200 shares issued 17/12/18 after exercise of listed options (LR 7.2 Ex 4) 100,000,000 shares issued 17/12/18 with shareholder approval on 19/11/18 (LR7.1) 110,000,000 shares issued 24/12/18 and ratified on 28/2/19 (LR 7.4) 5,000,000 shares issued 8/1/19 after exercise of listed options (LR 7.2 Ex 4) 133,333,333 shares issued 15/1/19 upon conversion of convertible notes (LR 7.2 Ex 4) 241,815,011 shares issued 15/1/19 and ratified on 28/2/19 (LR 7.4) 10,000,000 shares issued 24/1/19 and ratified on 28/2/19 (LR 7.4) 3,000,000 shares issued 1/3/19 after exercise of listed	

01/08/2012 Appendix 3B Page 9

options (LR 7.2 Ex 4)

8,750,000 shares issued 7/3/18 with shareholder

approval on 19/11/18 (LR7.2 Ex 14)

<sup>+</sup> See chapter 19 for defined terms.

	4,100,000 shares issued 12/03/19 after exercise of listed options (LR 7.2 Ex 4)
	33,794,007 shares issued between 22/03/19 and 27/03/19 after exercise of listed options (LR 7.2 Ex 4)
	18,001,133 shares issued 5/3/19 upon vesting of performance rights (LR 7.2 Ex 4)
	18,750,000 shares issued 28/3/19 with shareholder approval on 28/2/19 (LR7.2 Ex 14)
	9,086,610 shares issued on 29/3/19 after exercise of listed options (LR 7.2 Ex 4)
	61,540,900 shares issued between 1/4/19 – 5/4/19 after exercise of listed options (LR 7.2 Ex 4)
	1,739,099,886 shares to be issued on or around 14/5/19 after exercise of listed options (LR 7.2 Ex 4)
Subtract the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12m period	-
"A"	5,375,252,319
Step 2: Calculate 15% of "	'A"
"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	806,287,848
Step 3: Calculate "C", the 7.1 that has already been	amount of placement capacity under rule used
Insert number of *equity securities issued or agreed to	13,333,333 shares issued 17/12/18 for services rendered by consultant
be issued in that 12 month period <i>not counting</i> those issued:	18,283,333 shares issued 21/1/19 upon conversion of loans
<ul> <li>Under an exception in rule</li> </ul>	2,466,667 shares issued 1/3/19 upon conversion of loans
7.2	35,660,250 shares issued 7/3/19 under an STI Plan
• Under rule 7.1A	20,000,000 shares issued 8/3/19 for services rendered by a consultant
With security holder approval under rule 7.1 or	7,142,857 shares issued 8/3/19 upon conversion of loans
rule 7.4	25,000,000 unlisted options issued at \$0.02 and expiring on 31/12/19 granted on 8/3/19 for services
Note: • This applies to equity	rendered by a consultant 25,000,000 unlisted options issued at \$0.03 and
securities, unless specifically excluded – not just ordinary	expiring on 31/12/19 granted on 8/3/19 for services rendered by a consultant
securities	46,402,600 shares issued on 29/3/19 in consideration

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 10 04/03/2013

the securities the subject of the Appendix 3B to which this form is annexed  It may be useful to set out issues of securities on different dates as separate line items	1,428,571 shares issued on 29/3/19 upon conversion of a loan 5,000 shares to be issued on or around 15/4/19 after the closing date under the Prospectus
"C"	194,722,611
Step 4: Subtract "C" from placement capacity under	["A" x "B"] to calculate remaining rule 7.1
"A" x 0.15	806,287,848
Note: number must be same as shown in Step 2	
Subtract "C"	194,722,611
Note: number must be same as shown in Step 3	
Total ["A" x 0.15] – "C"	611,565,237
	Note: this is the remaining placement capacity under rule 7.1

<sup>+</sup> See chapter 19 for defined terms.

# Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	5,375,252,319	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	537,525,232	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	13,658,333 shares issued 13/2/19 upon conversion of loans	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	62,500,000 shares issued on 13/2/19 to raise \$500,000 equity at a price of \$0.008	
"E"	76,158,333	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	537,525,232	
Note: number must be same as shown in Step 2		
Subtract "E"	76,158,333	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	461,366,899	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.